ALAMEDA, Calif.--(BUSINESS WIRE)-- Santa Ana Bio, Inc., a precision immunology company developing targeted therapies for patients with autoimmune and inflammatory diseases, today announced the ...
--Investor syndicate includes founding investor Versant Ventures, GV, TPG, Access Biotechnology, a16z Bio + Health and RTW-- ALAMEDA, Calif.--(BUSINESS WIRE)--Santa Ana Bio, a precision immunology ...
Santa Ana Bio Inc. launched with combined series A and B rounds that pulled down $168 million for its precision immunology push in inflammatory diseases, with an aim of entering the clinic next year ...
Santa Ana Bio Inc. has emerged from stealth with $168 million in combined series A and B funding and a focus on developing targeted therapies for patients with autoimmune and inflammatory diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results